dc.contributor.author | Boon, E | |
dc.contributor.author | Valstar, MH | |
dc.contributor.author | van der Graaf, WTA | |
dc.contributor.author | Bloemena, E | |
dc.contributor.author | Willems, SM | |
dc.contributor.author | Meeuwis, CA | |
dc.contributor.author | Slootweg, PJ | |
dc.contributor.author | Smit, LA | |
dc.contributor.author | Merkx, MAW | |
dc.contributor.author | Takes, RP | |
dc.contributor.author | Kaanders, JHAM | |
dc.contributor.author | Groenen, PJTA | |
dc.contributor.author | Flucke, UE | |
dc.contributor.author | van Herpen, CML | |
dc.date.accessioned | 2019-03-05T16:39:54Z | |
dc.date.issued | 2018-07 | |
dc.identifier.citation | Oral oncology, 2018, 82 pp. 29 - 33 | |
dc.identifier.issn | 1368-8375 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3140 | |
dc.identifier.eissn | 1879-0593 | |
dc.identifier.doi | 10.1016/j.oraloncology.2018.04.022 | |
dc.description.abstract | OBJECTIVES:In 2010, a new subtype of salivary gland cancer (SGC), (mammary analogue) secretory carcinoma (SC), was defined, characterized by the ETV6-NTRK3 fusion gene. As clinical behavior and outcome data of this histological subtype tumor are still sparse, we aimed to describe the clinicopathological course and outcome of a series of translocation positive SC patients. PATIENT AND METHODS:We re-evaluated the pathological diagnosis of a subset of SGCs, diagnosed in 4 of 8 Dutch head and neck centers. Subsequently, tumors with a morphological resemblance to SC were tested for the ETV6-NTRK3 fusion gene using RT-PCR. Furthermore, patients prospectively diagnosed with SC were included. The clinical characteristics and outcomes were retrieved from the patient files. RESULTS:Thirty-one patients with ETV6-NTRK3 fusion gene positive SC were included. The median age was 49 years, 17 patients (55%) were male. Eighteen tumors (58%) arose in the parotid gland. One patient presented with lymph node metastasis. All patients underwent tumor resection and 4 patients had a neck dissection. Four patients had re-resection and 15 patients (48%) received postoperative radiotherapy. One patient developed a local recurrence, no regional recurrences or distant metastases were observed. After a median follow-up of 49 months the 5- and 10-year overall survival were 95%, the 5- and 10-year disease free survival were 89%. CONCLUSION:The clinical course of SC is favorable with a low rate of locoregional recurrence and excellent survival. Given the low incidence of nodal metastases, elective neck treatment, i.e. surgery and/or radiotherapy, does not seem to be indicated. | |
dc.format | Print-Electronic | |
dc.format.extent | 29 - 33 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Humans | |
dc.subject | Salivary Gland Neoplasms | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Oncogene Proteins, Fusion | |
dc.subject | Survival Analysis | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Young Adult | |
dc.title | Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-04-26 | |
rioxxterms.versionofrecord | 10.1016/j.oraloncology.2018.04.022 | |
rioxxterms.licenseref.startdate | 2018-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Oral oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.publication-status | Published | |
pubs.volume | 82 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical and Translational Sarcoma | en_US |
dc.contributor.icrauthor | van der Graaf, Wilhelmina | |